Marquez-Megias, S.; Ramon-Lopez, A.; Más-Serrano, P.; Diaz-Gonzalez, M.; Candela-Boix, M.R.; Nalda-Molina, R.
Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease. Pharmaceutics 2021, 13, 1244.
https://doi.org/10.3390/pharmaceutics13081244
AMA Style
Marquez-Megias S, Ramon-Lopez A, Más-Serrano P, Diaz-Gonzalez M, Candela-Boix MR, Nalda-Molina R.
Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease. Pharmaceutics. 2021; 13(8):1244.
https://doi.org/10.3390/pharmaceutics13081244
Chicago/Turabian Style
Marquez-Megias, Silvia, Amelia Ramon-Lopez, Patricio Más-Serrano, Marcos Diaz-Gonzalez, Maria Remedios Candela-Boix, and Ricardo Nalda-Molina.
2021. "Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease" Pharmaceutics 13, no. 8: 1244.
https://doi.org/10.3390/pharmaceutics13081244
APA Style
Marquez-Megias, S., Ramon-Lopez, A., Más-Serrano, P., Diaz-Gonzalez, M., Candela-Boix, M. R., & Nalda-Molina, R.
(2021). Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease. Pharmaceutics, 13(8), 1244.
https://doi.org/10.3390/pharmaceutics13081244